CN110327471B - Antispasmodic agent for endoscopy and preparation method thereof - Google Patents
Antispasmodic agent for endoscopy and preparation method thereof Download PDFInfo
- Publication number
- CN110327471B CN110327471B CN201910677597.6A CN201910677597A CN110327471B CN 110327471 B CN110327471 B CN 110327471B CN 201910677597 A CN201910677597 A CN 201910677597A CN 110327471 B CN110327471 B CN 110327471B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- antifoaming agent
- ultrasonic
- defoaming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 238000001839 endoscopy Methods 0.000 title claims description 26
- 239000000812 cholinergic antagonist Substances 0.000 title claims description 23
- 229940124575 antispasmodic agent Drugs 0.000 title claims description 3
- 239000002518 antifoaming agent Substances 0.000 claims abstract description 54
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 230000002048 spasmolytic effect Effects 0.000 claims description 20
- 239000006185 dispersion Substances 0.000 claims description 19
- 238000000227 grinding Methods 0.000 claims description 17
- -1 polydimethylsiloxane Polymers 0.000 claims description 16
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 16
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 7
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 claims description 7
- 230000001186 cumulative effect Effects 0.000 claims description 7
- 239000001540 sodium lactate Substances 0.000 claims description 7
- 229940005581 sodium lactate Drugs 0.000 claims description 7
- 235000011088 sodium lactate Nutrition 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000004570 mortar (masonry) Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 claims description 2
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000002834 transmittance Methods 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001215 inhibitory effect on spasm Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Abstract
The invention provides an endoscopic spasmolysis defoaming agent and a preparation method thereof, wherein the defoaming agent comprises 1-3 parts of L-menthol, 0.5-1 part of surfactant, 0.05-0.1 part of defoaming agent and 65-75 parts of purified water.
Description
Technical Field
The invention belongs to the field of preparations for endoscopy, and particularly relates to a spasmolytic antifoaming agent for endoscopy and a preparation method thereof.
Background
High-definition endoscopes are often used for examining the disease focus condition in the gastrointestinal tract in medical treatment, however, mucus and foam in the gastrointestinal tract often affect the visual field of the endoscope, so that the detection rate of tiny disease focus is low, and the examination time is prolonged; excessive contraction of the gastrointestinal tract may then prevent proper diagnosis and may allow minor lesions, such as small-sized cancerous sites, to be missed.
In order to solve the above problems during endoscopy, CN1893982A discloses a menthol-containing formulation which is an emulsion containing L-menthol, a surfactant and an antifoaming agent, is used for inhibiting smooth muscle contraction, and can maintain stability for a long time, exhibiting high light transmittance. However, the content of the defoaming agent in the emulsion is low, and if the content of the defoaming agent is increased, the solubility of the defoaming agent is lowered, and the defoaming agent precipitates from the emulsion, and the defoaming agent in the emulsion is only used for eliminating bubbles existing during the use of the emulsion, and cannot eliminate bubbles existing in gastric juice.
Disclosure of Invention
In order to solve the technical problems, the invention provides the defoaming agent special for endoscopy, and the defoaming agent can be used independently, has a defoaming effect and also has good light transmittance.
The specific technical scheme of the invention is as follows:
the invention provides a spasmolytic defoaming agent for endoscopy, which comprises the following components in parts by weight:
l-menthol 1-3 surfactant 0.5-1
0.05-0.1 of defoaming component and 65-75 of purified water.
In a further improvement, the defoaming component is a mixture of 0.02-0.04 parts of sodium cholate and 0.03-0.06 parts of polydimethylsiloxane.
In a further improvement, the sodium cholate and the polydimethylsiloxane form a dispersion, and the dispersion is prepared by the following method: placing sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 20-30min at the rotation speed of 500rpm, reversely continuing grinding for 20-30min at the rotation speed of 500rpm, taking out, and sieving with a 120-mesh sieve to obtain the dispersion.
In a further improvement, the surfactant comprises the following components in parts by weight:
polyethylene glycol 15000.05-0.2 octadecyl trimethyl ammonium chloride 0.35-0.5
Sodium lactate 0.1-0.3.
In a further improvement, the defoaming agent also comprises 1-3 parts by weight of liquiritigenin.
The invention also provides a preparation method of the spasmolytic antifoaming agent for endoscopy, which comprises the following steps: adding surfactant into purified water, stirring at 500rpm for 7min, standing, adding L-menthol and defoaming component into the above solution, and performing ultrasonic treatment to obtain defoaming agent.
Preferably, the conditions of the ultrasound are: 15-20 ℃, the ultrasonic power is 65-75w, the ultrasonic time is 3-5s, the interval time is 4-5s, and the cumulative ultrasonic time is 30-35 min.
The invention provides a spasmolytic defoaming agent for endoscopy, which has very good foam inhibition capability in gastrointestinal environment, high defoaming speed and light transmittance remarkably superior to that of the existing emulsion and defoaming agent.
Detailed Description
Example 1
Example 2
The sodium cholate and the polydimethylsiloxane form a dispersion, and the preparation method of the dispersion comprises the following steps: and (2) placing the sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 20min at the rotating speed of 500rpm, reversely continuing grinding for 20min at the rotating speed of 500rpm, taking out, and sieving by a 120-mesh sieve to obtain the dispersion.
Example 3
The preparation method of the spasmolytic antifoaming agent for endoscopy comprises the following steps:
adding polyethylene glycol 1500, octadecyl trimethyl ammonium chloride and sodium lactate into purified water, stirring at 500rpm for 7min, standing, adding L-menthol and sodium cholate and polydimethylsiloxane into the above solution, and performing ultrasonic treatment to obtain defoaming agent under the following conditions: the ultrasonic temperature is 15 ℃, the ultrasonic power is 65w, the ultrasonic time is 5s, the interval time is 4s, and the cumulative ultrasonic time is 35 min.
Example 4
The sodium cholate and the polydimethylsiloxane form a dispersion, and the preparation method of the dispersion comprises the following steps: placing sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 30min at the rotation speed of 500rpm, reversely continuing grinding for 30min at the rotation speed of 500rpm, taking out, and sieving with a 120-mesh sieve to obtain the dispersion.
The preparation method of the spasmolytic antifoaming agent for endoscopy comprises the following steps:
adding polyethylene glycol 1500, octadecyl trimethyl ammonium chloride and sodium lactate into purified water, stirring at 500rpm for 7min, standing, adding L-menthol and the dispersion into the solution, and performing ultrasonic treatment to obtain defoaming agent, wherein the ultrasonic treatment conditions are as follows: the ultrasonic temperature is 20 ℃, the ultrasonic power is 75w, the ultrasonic time is 3s, the interval time is 4s, and the cumulative ultrasonic time is 30 min.
Example 5
Example 6
Example 7
The preparation method of the spasmolytic antifoaming agent for endoscopy comprises the following steps:
adding polyethylene glycol 1500, octadecyl trimethyl ammonium chloride and sodium lactate into purified water, stirring at 500rpm for 7min, standing, adding L-menthol, sorbitol, polyacrylic acid, carbomer, sodium cholate and polydimethylsiloxane into the above solution, and performing ultrasonic treatment to obtain defoaming agent under the following conditions: the ultrasonic temperature is 17 ℃, the ultrasonic power is 70w, the ultrasonic time is 4s, the interval time is 5s, and the cumulative ultrasonic time is 35 min.
Example 8
The sodium cholate and the polydimethylsiloxane form a dispersion, and the preparation method of the dispersion comprises the following steps: placing sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 30min at the rotation speed of 500rpm, reversely continuing grinding for 30min at the rotation speed of 500rpm, taking out, and sieving with a 120-mesh sieve to obtain the dispersion.
The preparation method of the spasmolytic antifoaming agent for endoscopy comprises the following steps:
adding polyethylene glycol 1500, octadecyl trimethyl ammonium chloride and sodium lactate into purified water, stirring at 500rpm for 7min, standing, adding L-menthol, sorbitol, polyacrylic acid, carbomer, and dispersoid into the above solution, and performing ultrasonic treatment to obtain defoaming agent, wherein the ultrasonic treatment conditions are as follows: the ultrasonic temperature is 16 ℃, the ultrasonic power is 68w, the ultrasonic time is 4s, the interval time is 5s, and the cumulative ultrasonic time is 35 min.
Example 9
The sodium cholate and the polydimethylsiloxane form a dispersion, and the preparation method of the dispersion comprises the following steps: placing sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 30min at the rotation speed of 500rpm, reversely continuing grinding for 30min at the rotation speed of 500rpm, taking out, and sieving with a 120-mesh sieve to obtain the dispersion.
The preparation method of the spasmolytic antifoaming agent for endoscopy comprises the following steps:
adding polyethylene glycol 1500, octadecyl trimethyl ammonium chloride and sodium lactate into purified water, stirring at 500rpm for 7min, standing, adding L-menthol and dispersoid and glycyrrhizin into the above solution, and performing ultrasonic treatment to obtain defoaming agent, wherein the ultrasonic conditions are as follows: the ultrasonic temperature is 20 ℃, the ultrasonic power is 75w, the ultrasonic time is 3s, the interval time is 4s, and the cumulative ultrasonic time is 30 min.
Example 10
The preparation method is the same as example 9.
Example 11
The preparation method is the same as example 9.
Comparative example 1
CN1893982A emulsion disclosed in example 1.
Comparative example 2
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that in example 3.
Comparative example 3
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that in example 3.
Comparative example 4
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that in example 3.
Comparative example 5
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that in example 3.
Comparative example 6
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that in example 3.
Comparative example 7
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that of example 5.
Comparative example 8
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that of example 5.
Comparative example 9
The preparation method of the spasmolytic antifoaming agent for endoscopy is the same as that of example 5.
Comparative example 10
The preparation method is the same as example 9.
Comparative example 11
The preparation method is the same as example 9.
Comparative example 12
The preparation method is the same as example 9.
Experimental example 1 defoaming Capacity test
Preparing artificial gastric juice and artificial intestinal juice according to the method in annex XA of the second part of Chinese pharmacopoeia 2010:
artificial gastric juice: taking 16.4mL of dilute hydrochloric acid, adding about 800mL of water and 10g of pepsin, shaking up, and adding water to dilute into 1000mL to obtain the finished product.
Artificial intestinal juice: namely phosphate buffer (containing pancreatin) (pH 6.8).
Dividing 30mL bottles into four groups, and placing 10mL of artificial gastric juice in each bottle of the first group and the second group; the bottles of the third and fourth groups were filled with 10mL of artificial intestinal juice, then 10mL of the antifoaming agent provided in the examples and comparative examples of the present invention was placed in the first and third groups at 25 ℃ and 10mL of the antifoaming agent provided in the examples and comparative examples of the present invention was placed in the second and fourth groups at 37 ℃, the temperature of each group was maintained, the mixture was shaken on a shaker (200r/min) for 1min, and after 1min, the foam disappearance time T and the light transmittance Y were measured, and the results are shown in Table 1.
TABLE 1 defoaming Capacity test results of examples and comparative examples
As can be seen from the table, the anti-spasm agent for endoscopy provided by the present invention has a light transmittance significantly better than that of the control group when detected in the artificial gastric juice or the artificial intestinal juice at 25 ℃ or 37 ℃, and the defoaming time is significantly lower than that of the control group, and from the experimental data of the control example 1, the emulsion provided by the control example 1 has a good light transmittance at a pH of 7 and a temperature of 25 ℃, and the defoaming time is short, and when detected in the artificial gastric juice or the artificial gastric juice at 37 ℃, the light transmittance is significantly lower than that of the anti-spasm agent provided by the present application, and the defoaming time is significantly prolonged. And as can be seen from the above table, the defoaming component significantly affects the defoaming time, and the surfactant significantly affects the light transmittance.
Therefore, when the endoscopic spasmolysis defoaming agent provided by the invention is used for gastrointestinal endoscopy, the gastrointestinal endoscopy light transmittance can be obviously improved, and the defoaming time can be obviously shortened.
Experimental example 2 adsorption experiment
A protein solution having a gastrointestinal protein concentration of 1.0mg/mL was prepared using a phosphate buffer solution (pH6.8), and the antifoaming agents (microsphere content of 0.3g) of the examples and comparative examples provided in the present invention were added to a test tube containing the protein solution (0.3mL), respectively, and shaken (120r/min) in a constant temperature shaker at 37 ℃ for 4 hours, and then the protein content in the solution was measured. The protein adsorption on the microspheres was calculated from the amount of protein before and after adsorption, and the protein adsorption rate (initial protein amount-4 h post protein amount)/initial protein amount 100%, and the adsorption rate for each group of proteins is shown in table 2.
TABLE 2 adsorption test results of examples and comparative examples
| Sample (I) | Adsorption Rate (%) |
| Example 7 | 45.6 |
| Comparative example 7 | 0 |
| Comparative example 8 | 2.3 |
| Comparative example 9 | 8.3 |
As can be seen from the table, the defoaming agent provided by the invention has a certain adsorption effect on gastrointestinal proteins, so that the defoaming agent provided by the invention has a certain protein adsorption effect, can adsorb proteins adhered to the intestinal wall into the defoaming agent, further improves the definition of gastrointestinal examination, and improves the accuracy of examination.
EXAMPLE 3 spasm inhibition experiment
SD rats, body weight 200-;
rats were divided into 6 groups, 1 group for administration, 2 groups for administration, 1 group for control, 2 groups for control, 3 groups for control and blank control, and after fasting for 12 hours, the rats were administered as follows:
administration of 1 group 5mL of the antifoaming agent of example 1 of the present invention was administered by intragastric administration;
administration 2 groups 5mL of the antifoaming agent of example 9 of the present invention were intragastrically administered;
5mL of the antifoaming agent of comparative example 10 of the present invention was administered to the group of control 1 by gavage;
5mL of the antifoaming agent of comparative example 11 of the present invention was administered to the control group 2 by gavage;
5mL of the antifoaming agent of comparative example 12 of the present invention was administered to the control group 3 by gavage;
the blank control group was given an equal volume of saline.
Calculated using the conventional method, the inhibition ratio (%) was (average tension after KCl administration-average tension after administration)/(average tension after KCl administration-resting tension) x 100%, and the inhibition ratio results for each group are shown in table 3.
TABLE 3 results of spasm inhibition experiments in each group
| Group of | Inhibition ratio (%) |
| Blank control group | 7.56±1.23 |
| Administration of 1 group | 65.94±2.37 |
| Administration of 2 groups | 90.68±5.66 |
| Control 1 group | 22.38±2.82 |
| Control 2 group | 60.32±1.57 |
| Control 3 group | 61.55±2.96 |
As can be seen from the table, the antifoaming agent provided by the embodiment of the present invention has a significant inhibitory effect on spasm of colon, and as can be seen from the table, glycyrrhizin and L-menthol have a synergistic effect.
Claims (5)
1. The antispasmodic agent for endoscopy is characterized by comprising the following components in parts by weight:
l-menthol 1-3 surfactant 0.5-1
0.05-0.1 of defoaming component and 65-75 of purified water;
the defoaming component is a mixture of 0.02-0.04 parts of sodium cholate and 0.03-0.06 parts of polydimethylsiloxane;
the sodium cholate and the polydimethylsiloxane form a dispersion, and the preparation method of the dispersion comprises the following steps: placing sodium cholate in a mortar, slowly adding polydimethylsiloxane while grinding, grinding for 20-30min at the rotation speed of 500rpm, reversely continuing to grind for 20-30min at the rotation speed of 500rpm, taking out, and sieving with a 120-mesh sieve to obtain a dispersion;
the surfactant comprises the following components in parts by weight:
polyethylene glycol 15000.05-0.2 octadecyl trimethyl ammonium chloride 0.35-0.5
Sodium lactate 0.1-0.3.
2. The endoscopic spasmolytic antifoaming agent according to claim 1, further comprising 0.01 to 0.05 parts by weight of sorbitol, 0.2 to 0.4 parts by weight of polyacrylic acid, and 0.7 to 1.2 parts by weight of carbomer.
3. The endoscopic spasmolytic antifoaming agent according to claim 1, wherein the antifoaming agent further comprises 1-3 parts by weight of liquiritigenin.
4. A method for preparing an endoscopic spasmolytic antifoaming agent according to claim 1, comprising the steps of: adding surfactant into purified water, stirring at 500rpm for 7min, standing, adding L-menthol and defoaming component into the above solution, and performing ultrasonic treatment to obtain defoaming agent.
5. The method of claim 4, wherein the sonication conditions are: the ultrasonic temperature is 15-20 ℃, the ultrasonic power is 65-75w, the ultrasonic time is 3-5s, the interval time is 4-5s, and the cumulative ultrasonic time is 30-35 min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910070037 | 2019-01-24 | ||
| CN2019100700374 | 2019-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327471A CN110327471A (en) | 2019-10-15 |
| CN110327471B true CN110327471B (en) | 2021-08-27 |
Family
ID=68147500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910677597.6A Active CN110327471B (en) | 2019-01-24 | 2019-07-25 | Antispasmodic agent for endoscopy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110327471B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893982A (en) * | 2003-06-30 | 2007-01-10 | 日本制药株式会社 | Menthol-containing preparation |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN106177971A (en) * | 2016-07-20 | 2016-12-07 | 贵州理工学院 | Potato starch capsule shells containing menthol |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070148099A1 (en) * | 2005-12-27 | 2007-06-28 | Burke Susan E | Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants |
-
2019
- 2019-07-25 CN CN201910677597.6A patent/CN110327471B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893982A (en) * | 2003-06-30 | 2007-01-10 | 日本制药株式会社 | Menthol-containing preparation |
| CN102038963A (en) * | 2003-06-30 | 2011-05-04 | 日本制药株式会社 | Method for preparing a stabilised menthol emulsion |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN106177971A (en) * | 2016-07-20 | 2016-12-07 | 贵州理工学院 | Potato starch capsule shells containing menthol |
Non-Patent Citations (2)
| Title |
|---|
| "Pharmacology and preclinical pharmacokinetics of peppermint oil";H.-G. Grigoleit et al;《Phytomedicine》;20051231;第12卷;第612-616页 * |
| "多效内窥镜乳的制备及质量控制";曾玉兰;《北方药学》;20051231;第12卷(第8期);第11页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110327471A (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1147472C (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
| CN1250293C (en) | Drug composites | |
| EP0245855B1 (en) | Sucralfate preparations for application on esophagus mucosa | |
| EP0349235A2 (en) | Niacin and guar-gum containing composition | |
| JPH10298110A (en) | Liquid antacid preparation | |
| US20180311190A1 (en) | Benzenesulfonamide derivatives and method for treating cancer | |
| CN110354248A (en) | Application of the peptidomimetic aldehyde compound in preparation treatment swine fever virus (ASFV) infectious disease drug | |
| CN1294511A (en) | Medicinal compsns. | |
| CN110327471B (en) | Antispasmodic agent for endoscopy and preparation method thereof | |
| JP2008540403A (en) | Stabilized oral pharmaceutical composition of cephalosporin | |
| CN1646172A (en) | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation | |
| CN110314134B (en) | Auxiliary water for gastrointestinal endoscopy and preparation method thereof | |
| RU97104483A (en) | SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT | |
| CN102716076A (en) | Ambroxol hydrochloride medicine combination for injection | |
| JP4959335B2 (en) | Methylphenidate solution and related administration and manufacturing methods | |
| CN114288385B (en) | Preparation method of octreotide acetate preparation | |
| CN1172433A (en) | Sucralfate preparation | |
| CN102917586A (en) | Hypersulfated glucopyranosides | |
| JP3164455B2 (en) | Stratum corneum repair promoter | |
| CN101756949A (en) | Composition of ambroxol hydrochloride and cysteine and preparation method thereof | |
| CN1711247A (en) | Celecoxib prodrug | |
| AU742761B2 (en) | Pharmaceutical suspension comprising nevirapine hemihydrate | |
| EP0990438A1 (en) | Heat stable antacid and antigas suspensions | |
| CN101049312A (en) | Composition of medication, preparation method and application | |
| CN103980339B (en) | Accumulated snow oxalyl-L-Trp and preparing the application in antidepressant drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210527 Address after: 100094 No. 4009-14, 4th floor, block B, building 1, yard 2, Yongcheng North Road, Haidian District, Beijing Applicant after: Onas (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: 100102 room 310, 3rd floor, building 605, wangjingyuan, Chaoyang District, Beijing Applicant before: BEIJING GEFEI MEDICAL DEVICES Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231101 Address after: Room 6619, 6th Floor, Building 2, No. 9 Xiaotun Road, Fengtai District, Beijing, 100141 Patentee after: Beijing Yiliya Medical Technology Co.,Ltd. Address before: 100094 No. 4009-14, 4th floor, block B, building 1, yard 2, Yongcheng North Road, Haidian District, Beijing Patentee before: Onas (Beijing) Pharmaceutical Technology Co.,Ltd. |